Immunotherapy has been making rapid advancements as of late, especially the area of CAR T-cell therapy. Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks about the promising outlook for CAR T-cells in the treatment of a variety of blood cancers, before discussing their potential applications in solid tumors. While these investigations are still in their early days, Dr Burris explains his hope that as technologies develop, so too will the area of personalized medicine. He concludes his interview by mentioning personalized cancer vaccines, vaccines tailor-made for the patient based on the genome of their tumor. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
